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CC BY-NC-ND license (http://creativeBackground: According to the World Health Organization, HIV-transmitted drug resistance
(TDR) is increasing. We analyzed voluntary counseling test data from a hospital in Southern
Taiwan to investigate the TDR pattern in Southern Taiwan, the potential relationship between
sexual behavior and HIV transmission, and HIV drug-resistant strain transmission.
Methods: Genotypic resistance assays were performed on treatment-naı¨ve HIV patients re-
cruited from voluntary counseling testing (VCT) in Southern Taiwan from 2007 to 2011. Drug
resistance-associated mutations were interpreted with Stanford University HIV Drug Resis-
tance Database HIVdb program. Socio-demographics and sexual activity were recorded from
the VCT questionnaire. Logistic regression analysis was used to analyze the risk factors for
TDR, and a phylogenetic tree was constructed to elucidate the pattern of HIV drug-
resistant strains.
Results: Among the 161 treatment-naı¨ve HIV-infected patients, most were men who reported
having sex with men. The overall TDR rate was 10.6%. Patients with a history of sexually
transmitted diseases had a 7.8-fold higher risk of becoming infected with genotypic resistant
strains.Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st
o.com.tw (H.-C. Tsai), ssjlee@gmail.com (S.S.-J. Lee).
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488 Y.-W. Weng et al.Conclusion: In Southern Taiwan, the HIV TDR rate was 10.6% among those receiving VCT. Our
findings suggest that sexual behavior may play an important role in HIV drug-resistant strain
transmission.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
With the widespread use of antiretroviral therapy, the
emergence of drug-resistant human immunodeficiency virus
(HIV) has started to compromise successful clinical out-
comes in both treatment-naı¨ve and -experienced pa-
tients.1,2 According to the World Health Organization’s
(WHO) HIV Drug Resistance Report in 2012, an increasing
number of countries are classified as having a moderate
prevalence of resistance.3 Drug-resistant HIV is therefore
an important public health concern.
In Taiwan, HIV infection is a notifiable disease. Since the
first HIV-1 infected patient was diagnosed in Taiwan in
1984, the number of cases reported has increased every
year. A total of 26,475 adults were reported as being
infected with HIV-1 by the end of 2013, most of whom
(14,162; 53.49%) were men who have sex with men (MSM) or
were bisexual. HIV continues to spread among this group in
Taiwan and globally.4 In Taiwan, facilities offering volun-
tary counseling testing (VCT) at no cost at the point of
delivery were established in 1997, and have been sponsored
continuously by the Taiwan Center for Disease Control since
then as a key strategy to promote access to an early diag-
nosis, to prevent infection with HIV and other sexually
transmitted diseases (STDs), and to stimulate referral to
treatment. Taiwanese citizens have access to free and
anonymous HIV testing. After reactive HIV enzyme-linked
immunosorbent assay (ELISA) or rapid test results have
been received, the patients are referred for confirmation,
treatment, and follow up. The treatment and follow-up
strategy are guided by Taiwan guidelines for HIV/AIDS
management. The Taiwanese government has provided
anti-retroviral therapy free of charge since its introduction
in April 1997. With more people becoming infected in
Taiwan, larger numbers of patients are starting anti-HIV-1
treatment and the risk of emerging drug-resistant HIV-1 is
increasing.
The primary HIV drug resistant rate is around 4e12%
across Asia, including 3.8% in China,5 7.7% in Japan,6 12% in
South Korea,7 4.9% in Thailand,8 and 8% in Northern
Taiwan.9 The difference in rates of resistance from the
previously-mentioned studies is probably due to the dif-
ferences in stages of infection in the patients at the time of
enrollment and different HIV transmission routes in these
studies. There are, however, no data on the prevalence of
local HIV drug resistance in Southern Taiwan, especially in
those receiving VCT.
Lai et al9 reported the epidemiology and impact of HIV-
transmitted drug resistance in Northern Taiwan; however,
the prevalence and pattern of HIV transmitted drug resis-
tance in Southern Taiwan remains uncertain. Because drug-resistant HIV strains may graduate stepwise to back-mutate
certain drug-resistance mutations in vivo in the absence of
ongoing drug selection pressure,10 patients who are diag-
nosed with HIV infection from VCT are more likely to be in
an early stage of HIV infection, and the mutation pattern
from them is more likely to reflect the true drug resistance
pattern. Thus, we undertook the present study to investi-
gate the recent HIV drug resistance pattern in Southern
Taiwan, especially in those diagnosed with HIV from VCT,
other than patients infected with HIV-1 who present with
opportunistic infections. Furthermore, we aimed to assess
the roles of sexual behavior, STDs, and viral hepatitis in
accelerating the spread of the HIV infection or even a HIV
drug-resistant strain.
Methods
Ethics statement
All participants were informed about the study procedures
and gave written informed consent. This study was
approved by the Institutional Review Board of Kaohsiung
Veterans General Hospital, Kaohsiung, Taiwan.
Study population
During the period 2007e2011, 8,866 patients who accessed
the VCT at Kaohsiung Veterans General Hospital completed
a questionnaire interview and underwent a 30-minute ses-
sion of integrated pre- and post-testing counseling. The
clients provided 3e5 mL of blood specimens for HIV and
syphilis serology tests. Of these, 327 (3.69%) samples were
reactive on HIV ELISA or rapid test. Those who tested pos-
itive for HIV were referred to clinical care for confirmation,
treatment, and follow up. In total, 199 patients who tested
positive on HIV ELISA or rapid test returned to our hospital
to receive treatment and were then enrolled in our study.
Data on HIV sequence and genotypic resistance were
available for 161 patients. The sequence results were un-
available for 38 patients due to low viral load, insufficient
plasma, or interfering substances in the blood. Tests to
determine CD4 cell count, plasma viral load, serological
markers for syphilis, hepatitis B and C, toxoplasmosis, and
amebiasis, as well as the cortisol level, liver, and renal
function were performed when the client returned to the
clinic after HIV infection was confirmed.
All survey questions in the questionnaire were self-
reported and included information regarding the following
items. Socio-demographics: age, sex, sexual orientation,
occupation and education levels; and sexual activity:
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intercourse, history of STDs, history of substance abuse,
frequency of condom use, reasons for HIV testing, and
testing history. The frequency of condom use was measured
on a four-point Likert-type scale in the format “always”,
“often”, “seldom”, and “never”. “History of STDs or not?”
and “With what kind of STDs have you been diagnosed?” are
open questions in our questionnaire. We did not perform a
further study specifically about the STDs that had been
diagnosed; however, syphilis, amebiasis, hepatitis B and C,
were screened as our usual practice in the clinic.
Serologic tests
Hepatitis B surface antigen (HBsAg) and anti-hepatitis C
antibody presence were determined using an HBsAg radio-
immunoassay and anti-HCV EIA kit (ARCHITECT i1000SR,
Abbott Laboratories, Abbott Park, IL, USA), respectively.
Rapid Plasma Reagent (Macro-Vue, Becton Dickinson and
Company, Franklin Lakes, NJ, USA) was used for syphilis
screening and Treponema pallidum particle agglutination
assay (SERODIA, Fujirebio Inc., Tokyo, Japan) was used for
confirming syphilis infection. Toxoplasmosis was screened
for using the Toxo IgG kit (VIDAS Toxo IgG II, bioMe´rieux,
Marcy l’Etoile, France). Amebiasis was determined using
the indirect erythrocyte agglutination kit (Cellognost
Amoebiasis, Siemens Healthcare Diagnostics, Erlangen,
Germany). Titers  1:16 were defined as positive. The
plasma HIV RNA load and CD4 cell count were quantified
using a Cobas Amplicor HIV-1 monitor test, version 1.5
(Roche Diagnostics Corporation, Indianapolis, IN, USA) and
FACSFlow (Becton Dickinson and Company), respectively.
Reverse transcription polymerase chain reaction
amplification and resistance testing
Protease and reverse transcriptase (PR-RT) were sequenced
on the basis of HIV-amplification products using a com-
mercial kit (Viroseq, version 2.8, Celera, Alameda, CA,
USA). To facilitate comparison with other studies, antire-
troviral resistance mutations were interpreted using the
Stanford University HIV Drug Resistance Database HIVdb
program. The patients classified as low-level resistance,
intermediate resistance and high-level resistance were
defined as having drug resistance. Multidrug resistance was
defined as having genotypic resistance to more than one
class of anti-retroviral agent. RT and polymerase chain re-
action amplification were carried out with appropriate
negative controls to detect any possible contamination
during the experiments.
Phylogenetic analysis
Phylogeny was inferred from the PR-RT sequences of about
1.2 kb. The sequences were aligned with the Clustal W
program in the MEGA (molecular evolutionary genetics
analysis) analytical package (version 5.0; MEGA, Tempe,
AZ, USA), with minor manual adjustments. The phyloge-
netic trees were constructed using the neighbor-joining
method on the Kimura two-parameter distance matrix in
the MEGA software, with the branching pattern beingcalculated from 1000 bootstrap replicates. Bootstrap
values > 700 of 1000 replicates were considered significant.
Reference sequences were retrieved from the Los Alamos
HIV database (http://www.hiv.lanl.gov), and included se-
quences of various subtypes across Asia region.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Descriptive statistics included
frequency analysis (percentages) for categorical variables
and medians with interquartile range (IQR) for continuous
variables. Categorical variables were compared using Chi-
square or Fisher’s exact tests, and non-categorical vari-
ables were compared using the Mann-Whitney U test. All
tests were two-tailed, and p < 0.05 was considered sig-
nificant. The parameters with p < 0.5 were then entered
into multivariate analysis.
Results
Baseline characteristics
From 2007 to 2011, through VCT at Kaohsiung Veterans
General Hospital, 199 patients were confirmed for HIV
infection, and all of them completed the questionnaire,
pretesting and post-testing counseling. Other 128 patients
who had ELISA or rapid test positive did not return to our
hospital for further survey. And 16 patients (16/128) didn’t
complete the questionnaire and were excluded for analysis.
There were no significant differences in baseline charac-
teristics (including age, marriage, and sexual behavior)
between those who returned for further treatment and
those who did not (data not shown). Females seem to have
been less willing to come back for a confirmation test
(pZ 0.04). The statistical difference here may be because
females make up a small group in our study population
(2.2%).
Among the 161 patients that completed the HIV viral
sequence, a total of 17 patients (10.6%) were infected with
HIV-1 subtype B strains that harbored mutations that were
resistant to any HIV drug. Resistance to non-nucleoside
reverse transcriptase inhibitors (NNRTIs) was most common
(n Z 14, 8.7%). The prevalence of transmitted drug resis-
tance from 2007 to 2011 is shown in Fig. 1, and the baseline
characteristics of the patients are summarized in Table 1.
Most of the patients (60.8%) were aged between 20 years
and 29 years. MSM or bisexual individuals were the largest
percentage of our population of HIV infected in our patient
group (87%). The median CD4 count was 347 cells/cumm
(IQR: 230e445/cumm), and the median viral load (Log10)
was 4.7 (IQR: 4.2e5.0). Overall, 10.1% of our screened
cases were hepatitis B carriers. Seven percent of our study
patients mentioned that they had a history of STDs, with
syphilis and condyloma acuminatum being those most often
mentioned. We interpreted the mutation points using the
Stanford University HIV Drug Resistance Database and found
that the V179D mutation was the most common mutation in
our study group (9/161, 5.6%), followed by a mutation at
position 103 (K103N, K103R, which accounted for 1.9% or 3/
161), and mutations at positions 106(V106I), 181(Y181C),
Table 1 Comparisons of the baseline characteristics of the
sequences
No res
(n Z 1
Baseline demographic data
Median age, y 26.0 (2
Married 7 (4
Illegal drug use or not 21 (1
Male sex 143 (9
Median CD 4 count, cells/mm3 337 (2
Median viral load, Log10 copies/mm
3 4.7 (4
HIV subtype B 141 (9
Co-infection
HBV carrier 14 (9
Anti-HCV(+) 3 (2
TPHA positive, syphilis 33 (2
IHA titers  1: 16 9 (6
Toxoplasma IgG positive 6 (4
Sexual behavior
Sexual orientation, n (%) MSM 104 (7
Bisexual 21 (1
Hetero 19 (1
No. of sexual partners >3 partners 39 (5
3 partners 36 (4
Anal intercourse 116 (8
History of STD 8 (5
Frequency of condom use Always + Usually 70 (5
Seldom + Never 64 (4
History of having had sex with HIV-infected partners 10 (7
Data are presented as n (%) or n (25e75% IQR).
HBVZ hepatitis B virus; HCVZ hepatitis C virus; IHAZ indirect hema
transmitted disease; TPHA Z Treponema pallidum hemagglutination
Figure 1. Prevalence of transmitted drug resistance of HIV-1
in Kaohsiung Veterans General Hospital from 2007 to 2011.
Frequency of resistance to protease inhibitors, nucleoside
reverse transcriptase inhibitors and non-nucleoside reverse
transcriptase inhibitors in treatment-naı¨ve HIV-infected in-
dividuals in each year is shown. MDR Z multidrug resistance;
NNRTIs Z non-nucleoside reverse transcriptase inhibitors;
NRTIs Z nucleoside reverse transcriptase inhibitors;
PI Z protease inhibitors; TDR Z transmitted drug resistance.
490 Y.-W. Weng et al.184 (M184V), 215 (T215S), 221 (H221Y), and 318 (Y318F),
accounting for 1.2% in total (2/161).
In univariate analysis, we found that a history of STDs
was statistically significantly associated with infection
with a resistant strain. For a more detailed analysis, the
presence of syphilis, amebiasis, and hepatitis C co-
infection was compared in patients infected with a resis-
tant HIV strain and those not so infected. No statistically
significant difference was noted for the STDs mentioned
above. There were no differences between patients with
TDR and those without TDR in terms of age, sex, risk
exposure, CD4 count, HIV viral load, HIV-1 subtype, hep-
atitis B co-infection, or HIV-1 RNA level. After multivar-
iate analysis, patients with a history of STDs were found to
be at a statistically significantly higher risk of being
infected with drug-resistant HIV strains, with an adjusted
odds ratio of 7.824 (95% confidence interval:
1.241e49.316; Table 2).
Phylogenetic analysis
The PR-RT sequence results of the 161 HIV-infected pa-
tients were aligned with reference sequences and sub-
jected to phylogenetic analysis. Fifteen clusters (bootstrap
values > 70%) were found within our study patients, with all
having only two members (Fig. 2). One cluster with twostudy subjects with and without genotypic-resistant viral
istant strain
44)
Resistant strain
(n Z 17)
Total (n Z 161) p
2.0e32.0) 26.0 (22.0e31.0) 26.0 (22.0e32.0) 0.66
.9) 0 (0.0) 7 (4.3) >0.99
5.1) 1 (5.9) 22 (14.1) 0.47
9.3) 17 (100.0) 160 (99.3) >0.99
46e438) 383 (172e496) 347 (230e445) 0.69
.1e5.0) 4.7 (4.4e5.0) 4.7 (4.2e5.0) 0.22
7.9) 17 (100.0) 158 (98.1) >0.99
.9) 2 (12.5) 16 (10.1) 0.67
.1) 0 (0.0) 3 (1.9) >0.99
3.6) 3 (18.8) 36 (23.1) >0.99
.8) 0 (0.0) 9 (6.2) >0.99
.6) 0 (0.0) 6 (4.2) >0.99
2.2) 10 (58.8) 114 (70.8) >0.99
4.6) 5 (29.4) 26 (16.1)
3.2) 2 (11.8) 21 (13.0)
2) 10 (71.4) 49 (55.1) 0.25
8) 4 (28.6) 40 (44.9)
4.1) 14 (82.4) 130 (83.9) 0.74
.8) 4 (23.5) 12 (7.7) 0.03
2.2) 10 (62.5) 80 (53.3) 0.6
7.8) 6 (37.5) 70 (46.7)
.1) 1 (5.9) 11 (7.0) >0.99
gglutination; MSMZmen who have sex with men; STDZ sexually
.
Table 2 Multivariate analysis of the risk factors associ-
ated with genotypic drug resistancea
p Adjusted
odds ratio
95% confidence
interval
Illegal drug use 0.174 0.202 0.020e2.032
HIV viral load 0.930 0.943 0.255e3.489
Number of sexual
partners
0.086 3.297 0.845e12.861
History of sexually
transmitted disease
0.029 7.824 1.241e49.316
a HIV-infected patients who had a history of sexually trans-
mitted disease had a 7.8-fold higher risk of harboring genotypic
drug resistant strains.
HIV transmitted drug resistance in Southern Taiwan 491patients with TDR was noted; however, the detailed history
did not show any relationship between these two patients.
The distribution of the TDR strain was diverse and there
were no obvious huge clusters in our patients.Figure 2. Phylogenetic analysis of 161 treatment-naı¨ve HIV-in
Alamos HIV database (http://www.hiv.lanl.gov) included various
2007e2011. The study and reference sequences were aligned by th
was constructed by the neighbor-joining method in MEGA software
with the relative genetic distance. Bootstrap values > 700 of 1,00
from the patients were labeled (solid diamond for resistant strain a
the same strain (bootstraps value Z 100%), which is marked withDiscussion
In the current study, we found that patients with a history
of STDs had a 7.8-fold higher risk of becoming infected
with a genotypic resistant strain of HIV. Male-to-male
sexual contact was the major route of HIV-1 spread in
our study population, which is consistent with the findings
of other studies performed in Taiwan11,12 and world-
wide.13,14 Sexual risk-taking behavior, including unpro-
tected receptive anal intercourse, multiple male sex
partners, and unprotected anal intercourse with HIV-
positive patients, were proved to be risk factors for HIV
infection in this group.15 In accordance with a previous
study reporting a trend towards an increase in syphilis
incidence rates among HIV-infected MSM, this study had
similar results.16 Several STDs have also been reported to
be risk factors for HIV transmission.17e19 A previous study
in Taiwan that enrolled VCT clients also found that clients
with at least one STD other than HIV had a significantly
higher prevalence of HIV infection than those without anyfected patients. Reference strains downloaded from the Los
subtypes (subtype B, C, CRF01_AE) across Asia region from
e Clustal W program with minor manual adjustments. The tree
version 5.0. The horizontal branch was drawn in accordance
0 replicates were considered significant. All of the sequences
nd circle for wild-type virus). Two clusters were infected with
a triangle.
492 Y.-W. Weng et al.other STDs.20 Although we did not find any drug resistance
transmission clusters in our patients, it is reasonable to
assume that patients with different STDs may have
engaged in risky sexual behavior, thereby increasing their
risk of HIV infection by damage to the mucosa membranes
and becoming infected with drug-resistant strains from
casual sexual partners. This hypothesis was further sup-
ported by the fact that the number of sexual partners was
also associated with an increased incidence of becoming
infected with a drug-resistant strain after adjusting for
illegal drug use, viral load, and history of STDs. Although
there was no statistically significant difference
(p Z 0.086), risky sexual behavior seems to play an
important role in HIV transmission, and even drug-resistant
HIV strain transmission. Reducing sexually risky behavior
may help to reduce the rate of drug-resistant HIV trans-
mission among MSM. Frequency of condom use did not,
however, show significance in acquisition of TDR virus in
our study. This may be due to our questionnaire’s being
self-reported, with participants writing answers by hand.
In this study, concerns about privacy may have led to a
reporting bias. In addition, some STDs cannot be totally
prevented by condom use, such as human papillomavirus,
or herpes simplex virus infection.
The prevalence of TDR to any antiretroviral therapy in
our patients was 10.6%. Genotypic resistance mutations
to nucleoside reverse transcriptase inhibitors and NNRTIs
were more commonly observed compared with those to
protease inhibitors. The overall TDR rate was higher than
a previous study performed in Northern Taiwan covering
the period from 2000 to 2010, which reported an anti-
retroviral resistance rate of 8%.9 This may be due to the
different study populations enrolled. The study performed
in Northern Taiwan enrolled patients infected with HIV
and who received HIV care at the National Taiwan Uni-
versity Hospital. The median CD4 count in that study
was 105 cells/mm3. Our study enrolled VCT clients who
may have been in an early stage of HIV infection, with a
median CD4 count of 347 cells/mm3. Several studies21e23
have shown that resistant strains are replaced by a
wild-type virus at different rates depending on the mu-
tation point. Nucleotide reverse transcription inhibitor
mutations show the greatest variation in persistence, such
as the M184V mutation which becomes undetectable
in population sequencing substantially faster than the
other mutation groups.21,23 The genotypic resistance
to NNRTIs was 8.7% in our study population. Because
NNRTIs are the backbone of first-line anti-retroviral
therapy, further large-scale studies conducted on the
transmission patterns or trends in drug resistance are
important.
The V179D mutation conferred potential low-level
resistance to efavirenz, nevirapine, and etravirine, ac-
counting for 5.6% (9/161) of our study population, and was
the most frequently encountered mutation. The combina-
tion of K103R plus V179D, however, decreased nevirapine
and efavirenz susceptibility by more than 10-fold, and the
combination of V106I plus V179D was also synergistic at
reducing nevirapine and efavirenz susceptibility. Thus, in
our study population, only patients with V179D plus K103R
or V179D plus V106I were considered to have genotypic
drug resistance. The prevalence of V179D was relativelyhigh in the therapy-naı¨ve and the treatment-failure in-
dividuals.24,25 The prevalence of V179D in this study is
higher compared to previous studies in other Southeast
Asian countries such as 4.2e4.8% in Thailand8,26 and 3.2% in
other areas (Malaysia, Thailand, and Hong Kong).22 This
may be due to differences in the study populations,
different anti-retroviral therapy regimens, and HIV sub-
types. A recent study27 reported that V179D/E/T predicted
reduced Week 4 responses but not virologic failure. Thus,
the need to adjust the backbone regimen in Taiwan is un-
clear; continued molecular surveillance will be important
in further investigations.
In our phylogenetic tree (Fig. 2), only one cluster with
two TDR patients was noted, and there was no TDR strain
spreading in our study group. However, 14 clusters were
noted in the non-TDR patients, all of which had only two
members. Two clusters were infected with the same strain
(bootstraps value Z 100%), which is marked in Fig. 2 by a
triangle. Because highly related viral sequences may
correlate with shared social or risk-behavior patterns,
phylogenetic analysis has a potential public benefit in
identifying clusters of HIV transmission, and even in tracing
back the potential index case.28 In addition, a recent large
population survey in Switzerland29 showed that resistant
mutations are frequently transmitted among untreated
MSM individuals. Although the TDR strains were diverse in
our study population, applying routine phylogenetic anal-
ysis may offer more information about the transmission of
viruses.
This study has several limitations. First, the number of
our study cases was small compared with a previous study
performed in Northern Taiwan. It does, however, reflect
the TDR pattern in Southern Taiwan and focuses on pa-
tients from VCT who are more likely to be in an early stage
of HIV infection. This data aimed to reflect the true TDR
pattern. Second, because the makeup of our pool of par-
ticipants is so dominated by one group, this could skew our
results. The TDR in other populations with HIV infection
may be different: further investigations are needed to
elucidate this issue. Third, the data on sexual behavior and
history of STDs were obtained from questionnaires, and
whether the answers to these questionnaires were truthful
is unknown. Fourth, the present study did not investigate
the prevalence of some other STDs, such as infections with
human papillomavirus, herpes simplex viruses, Chlamydia
trachomatis, and Neisseria gonorrhoeae. As some of the
STDs could not be totally protected against through
condom use, a more detailed relationship between STDs
and resistant HIV-1 strain transmission needs further
investigation.
In summary, the TDR in HIV-infected patients seems to
be higher in Southern Taiwan. This may be because most of
our patients were in the early stage of HIV infection. In
addition to this, resistant HIV strains were significantly
more commonly found in patients with a history of STDs.
Further studies investigating the relationship between
resistant HIV strains and STDs are warranted.Conflicts of interest
All authors declare no conflicts of interest.
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